Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.66 |
| ▸ | MLYCD | O95822 | 2/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA7 | P43166 | 3/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4332741 | 0.87 | MAPK14 (0.73) | MAPK14MLYCDHSP90AA1CA1CA2 | |
| SCHEMBL4335420 | 0.81 | MAPK14 (0.75) | MAPK14MLYCD | |
| SCHEMBL4329157 | 0.81 | MAPK14 (0.80) | MAPK14MLYCD | |
| SCHEMBL4338188 | 0.80 | MAPK14 (0.51) | MAPK14MLYCDHSP90AA1CSNK1D | |
| SCHEMBL4339564 | 0.80 | MAPK14 (0.56) | MAPK14MLYCDHSP90AA1BLMCSNK1D | |
| SCHEMBL4330141 | 0.80 | MAPK14 (0.76) | MAPK14MLYCD | |
| SCHEMBL4335643 | 0.80 | MAPK14 (0.50) | MAPK14MLYCDHSP90AA1 | |
| SCHEMBL4338186 | 0.80 | MAPK14 (0.64) | MAPK14MLYCD | |
| SCHEMBL4337134 | 0.79 | MAPK14 (0.56) | MAPK14MLYCDHSP90AA1CA1CA2 | |
| SCHEMBL4335579 | 0.79 | MAPK14 (0.70) | MAPK14MLYCDHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192164-A1 | Treating agent of inflammatory bowel disease | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-07-30 | — | — | US | claimed |
| EP-2044957-A1 | TREATMENT AGENT FOR INFLAMMATORY BOWEL DISEASE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | claimed |
| US-20090192164-A1 | Treating agent of inflammatory bowel disease | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| EP-2044957-A1 | TREATMENT AGENT FOR INFLAMMATORY BOWEL DISEASE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192164-A1 | Treating agent of inflammatory bowel disease | MAPK6, SLC10A2, MAP3K6 | MAPK14 13/4885MLYCD 2846/4885HSP90AA1 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.